ByteDance’s Anew Labs presents first AI-designed therapy as TikTok parent enters drug discovery race

ByteDance’s Anew Labs presents first AI-designed therapy as TikTok parent enters drug discovery race

https://thenextweb.com/news/bytedance-anew-labs-ai-drug-discovery

Publish Date: 2026-05-02 05:01:59

Source Domain: thenextweb.com

ByteDance’s drug discovery unit, Anew Labs, has showcased significant advancements at major immunology conferences, revealing its first AI-designed therapy targeting IL-17, formerly deemed undruggable. This small molecule is part of a broader effort to replace high-cost injectable antibody therapies with affordable oral small molecules, leveraging Anew Omni, a generative framework claiming to design functional molecules across various scales. Located in Shanghai, Singapore, and California, Anew Labs aims to leverage its AI expertise, originally honed for TikTok’s recommendation algorithm, to revolutionize drug discovery by handling vast molecular datasets and predicting binding affinities. While promising, the real test of Anew’s capabilities will lie in clinical trials and efficacy, as its IL-17 inhibitor presented thus far is only at the preclinical stage.

Key Points:
– Anew Labs presented an AI-designed molecule targeting IL-17, a previously undruggable protein, showcasing its generative AI’s potential in drug discovery.
– Anew Omni is an AI framework capable of generating functional molecules across different scales, which is a significant advancement in the field.
– The parent company’s valuation of $300 billion and advanced AI infrastructure position Anew Labs well in the competitive AI-driven drug discovery landscape.
– The challenges and lengthy process of drug development from initial model testing to clinical approvals remain significant hurdles.
– Whether Anew Labs can successfully translate its AI-designed molecules into market-ready therapies will ultimately need to be demonstrated through extensive clinical trials.